TABLE 2.

Measures of disease and lesion development in groups of guinea pigs given different HSV-2 vaccines

Vaccination group	Lesion ratea		Mean no. of recurrent lesion episodesb	Reduction in the no. of recurrent lesion days (%)c
	Acute phase	Recurrent phase
pVAX-FI-Mock	9/10	6/6d	3.67
pVAX-FI-HSV2	1/10	1/10	0.70f	79f
UL5, UL30, gD2t DNA-FI-HSV2	0/9e	2/9	0.22f	97f
UL29, UL52, gD2t DNA-FI-HSV2	1/10	4/10	0.90g	81g
gD2 subunit	1/10	3/10	0.80g	82g

^aThe lesion rate is the number of guinea pigs that developed at least one lesion/total number of guinea pigs during the acute phase (days 0 to 14 postchallenge) or recurrent phase (days 15 to 100 postchallenge). The values for all vaccine groups were significantly different (P ≤ 0.001) from the value for the control group (pVAX-FI-Mock) by Fisher's exact test.

^bA lesion episode is defined as one or more consecutive days with a disease score of 2 or above.

^cReduction in the cumulative number of recurrent lesion days per guinea pig compared to the number for the pVAX-FI-Mock group.

^dThree animals died before the recurrent phase; 1 survivor failed to resolve primary disease and was omitted.

^eOne animal did not recover from anesthesia used during challenge.

^fSignificantly different (P < 0.05) from the value for the pVAX-FI-Mock group by Kruskal-Wallis analysis plus Dunn's multiple-comparison test.

^gSignificantly different (P < 0.01) from the value for the pVAX-FI-Mock group by Kruskal-Wallis analysis plus Dunn's multiple-comparison test.